We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

WATERS CORPORATION

Waters Corp. designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performan... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Low Serotonin Levels Associated with Higher Nigral Iron in Parkinson’s Disease

By LabMedica International staff writers
Posted on 17 Jan 2022
Print article
Image: The Water’s Xevo triple-quadrupole mass spectrometry (TQ-S MS/MS) system (Photo courtesy of Duke University)
Image: The Water’s Xevo triple-quadrupole mass spectrometry (TQ-S MS/MS) system (Photo courtesy of Duke University)
Parkinson’s disease (PD) is a neurodegenerative disorder characterized clinically by bradykinesia, rigidity, and/or tremor and pathologically by dopaminergic neuron loss in the substantia nigra pars compacta (SNc) and the presence of ⍺-synuclein-containing inclusions in cell bodies or neurites (Lewy pathology).

Iron accumulation in the brain is common with aging and consistently reported to be increased in PD, particularly in the substantia nigra (and specifically the SNc). Low serotonin is thought to contribute to the high rate (~ 35%) of clinically significant depression, an often prodromal symptom, among patients. Lower CSF serotonin also has been associated with freezing of gait.

A team of Neurologist at Pennsylvania State University (Hershey, PA, USA) and their associates investigated whether lower plasma serotonin in PD is associated with higher nigral iron. They obtained plasma samples from 97 PD patients and 89 controls and MRI scans from a sub-cohort (62 PD, 70 controls).

For analysis of peripheral serum iron metrics (red blood cell count, hemoglobin, hematocrit, serum iron, transferrin, total iron binding capacity (TIBC), transferrin saturation) and platelet counts, blood was collected into a BD PST II plasma separator tube (Becton, Dickinson and Company, Franklin Lakes, NJ , USA), and analyzed by using standard assays.

Plasma serotonin concentrations were measured using an Acuity ultra-high-performance liquid chromatography (UPLC) I class and Xevo triple-quadrupole mass spectrometry (TQ-S MS/MS) system (Waters, Milford, MA, USA). Brain MRI scans were offered to all subjects, but completed by only a subset (70 controls, 62 PD patients) and were used for regional iron content using MRI-based quantitative susceptibility mapping.

The investigators reported that PD patients had lower mean plasma serotonin concentrations than controls [in log scale, 5.53 ± 1.40 versus 6.25 ± 0.85, P < 0.0001] and higher nigral iron content (SNc: p < 0.001) overall. The correlation appeared strongest in patients during the first year of diagnosis but waned in later stage disease, when an increasing number of influences on these features presumably come into play. However, the PD distribution appeared distinctly bimodal, and the group difference was driven by approximately one-third of patients with extremely low concentrations (the lowest tertile, n = 32; < 150 nM). In the remaining two-thirds of PD patients, plasma serotonin concentrations were distributed relatively widely and within the normal range of controls.

The authors concluded that there was a robust correlation between low plasma serotonin and higher iron content in the SNc in PD, which was absent in controls. This correlation was present even in patients within one year of diagnosis, suggesting it might also be present in the prodromal phase, and was stronger in the SNc than any other brain region examined. The study was published on December 21, 2021 in the journal Scientific Reports.

Related Links:
Pennsylvania State University
Becton, Dickinson and Company
Waters


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Molecular Diagnostics

view channel
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants,... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The medical office procedure detects the key biomarker in Parkinson’s and related neurodegenerative diseases (Photo courtesy of BIDMC)

Simple Skin Biopsy Test Detects Parkinson’s and Related Neurodegenerative Diseases

Parkinson's disease and a group of related neurodegenerative disorders known as synucleinopathies impact millions globally. These conditions, including Parkinson’s disease (PD), dementia with Lewy bodies... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.